LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers

Introduction The identification of the genetic risk factors that could discriminate non-thrombotic from thrombotic antiphospholipid antibodies (aPLA) carriers will improve prognosis of these patients. Several human studies have shown the presence of aPLAs associated with atherosclerotic plaque, which is a known risk factor for thrombosis. Hence, in order to determine the implication of atherosclerosis in the risk of developing thrombosis in aPLA positive patients, we performed a genetic association study with 3 candidate genes, APOH, LDLR and PCSK9. Material & Methods For genetic association study we analyzed 190 aPLA carriers -100 with non-thrombotic events and 90 with thrombotic events-and 557 healthy controls. Analyses were performed by chi(2) test and were corrected by false discovery rate. To evaluate the functional implication of the newly established susceptibility loci, we performed expression analyses in 86 aPLA carrier individuals (43 with thrombotic manifestations and 43 without it) and in 45 healthy controls. Results Our results revealed significant associations after correction in SNPs located in LDLR gene with aPLA carriers and thrombotic aPLA carriers, when compared with healthy controls. The most significant association in LDLR gene was found between SNP rs129083082 and aPLA carriers in recessive model (adjusted P-value = 2.55 x 10(-3); OR = 2.18; 95% CI = 1.49-3.21). Furthermore, our work detected significant allelic association after correction between thrombotic aPLA carriers and healthy controls in SNP rs562556 located in PCSK9 gene (adjusted P-value = 1.03 x 10(-2); OR = 1.60; 95% CI = 1.24-2.06). Expression level study showed significantly decreased expression level of LDLR gene in aPLA carriers (P-value < 0.0001; 95% CI 0.16-2.10; SE 0.38-1.27) in comparison to the control group. Discussion Our work has identified LDLR gene as a new susceptibility gene associated with the development of thrombosis in aPLA carriers, describing for the first time the deregulation of LDLR expression in individuals with aPLAs. Besides, thrombotic aPLA carriers also showed significant association with PCSK9 gene, a regulator of LDLR plasma levels. These results highlight the importance of atherosclerotic processes in the development of thrombosis in patients with aPLA.

Revision bibliográfica. Cuidados del catéter periférico

[ES]Los cateterismos venosos periféricos son los dispositivos que con mayor frecuencia se emplean en el acceso vascular para pacientes que se encuentran ingresados en unidades hospitalarias. Estos catéteres son reemplazados sistemáticamente cada tres o cuatro días para tratar de prevenir la flebitis como refleja la guía de Center for Disease control and prevention (CDC) y por extensión, nuestro sistema de salud de Osakidetza. Sin embargo, la evidencia que apoya esta práctica no está del todo cimentada.El objetivo de esta revisión bibliográfica es evaluar la efectividad de esta práctica clínica tan integrada en la vida diaria de los profesionales de enfermería mediante la evaluación de la evidencia científica existente hasta el momento.Se realizo una búsqueda exhaustiva en diferentes bases de datos electrónicas desde Octubre de 2012 hasta Abril del año 2013. Se descargaron los textos completos de aquellos artículos que pudiesen ser potencialmente útiles en el estudio y se analizaron bajo los criterios de inclusión y selección. Los siete artículos seleccionados como válidos no demuestran que sea necesario sustituir de forma sistemática el catéter venoso periférico así como lo defiende la CDC. Debido a ello, se podría abolir esta práctica clínica que reduciría significativamente el dolor y las molestias que sufren los pacientes día a día, el tiempo que el personal de enfermería dedica en este tipo de prácticas, además de todo el coste sanitario que ello con lleva.

Thrombotic Antiphospholipid Syndrome Shows Strong Haplotypic Association with SH2B3-ATXN2 Locus

Background : Thrombotic antiphospholipid syndrome is defined as a complex form of thrombophilia that is developed by a fraction of antiphospholipid antibody (aPLA) carriers. Little is known about the genetic risk factors involved in thrombosis development among aPLA carriers. Methods: To identify new loci conferring susceptibility to thrombotic antiphospholipid syndrome, a two-stage genotyping strategy was performed. In stage one, 19,000 CNV loci were genotyped in 14 thrombotic aPLA+ patients and 14 healthy controls by array-CGH. In stage two, significant CNV loci were fine-mapped in a larger cohort (85 thrombotic aPLA+, 100 non-thrombotic aPLA+ and 569 healthy controls). Results : Array-CGH and fine-mapping analysis led to the identification of 12q24.12 locus as a new susceptibility locus for thrombotic APS. Within this region, a TAC risk haplotype comprising one SNP in SH2B3 gene (rs3184504) and two SNPs in ATXN2 gene (rs10774625 and rs653178) exhibited the strongest association with thrombotic antiphospholipid syndrome (p-value = 5,9 × 10−4 OR 95% CI 1.84 (1.32–2.55)). Conclusion : The presence of a TAC risk haplotype in ATXN2-SH2B3 locus may contribute to increased thrombotic risk in aPLA carriers.

Monitorización avanzada en el posoperatorio de las cardiopatías congénitas : motorización hemodinámica avanzada en el posoperatorio de cardiopatías congénitas mediante termodilución transpulmonar y espectroscopia cercana al infrarrojo

196 p. : graf.

Efficacy and safety of autologous platelet rich plasma for the treatment of vascular ulcers in primary care: Phase III study

Background: Vascular ulcers are commonly seen in daily practice at all levels of care and have great impact at personal, professional and social levels with a high cost in terms of human and material resources. Given that the application of autologous platelet rich plasma has been shown to decrease healing times in various different studies in the hospital setting, we considered that it would be interesting to assess the efficacy and feasibility of this treatment in primary care. The objectives of this study are to assess the potential efficacy and safety of autologous platelet rich plasma for the treatment of venous ulcers compared to the conventional treatment (moist wound care) in primary care patients with chronic venous insufficiency (C, clinical class, E, aetiology, A, anatomy and P, pathophysiology classification C6). Design: We will conduct a phase III, open-label, parallel-group, multicentre, randomized study. The subjects will be 150 patients aged between 40 and 100 years of age with an at least 2-month history of a vascular venous ulcer assigned to ten primary care centres. For the treatment with autologous platelet rich plasma, all the following tasks will be performed in the primary care setting: blood collection, centrifugation, separation of platelet rich plasma, activation of coagulation adding calcium chloride and application of the PRP topically after gelification. The control group will receive standard moist wound care. The outcome variables to be measured at baseline, and at weeks 5 and 9 later include: reduction in the ulcer area, Chronic Venous Insufficiency Quality of Life Questionnaire score, and percentage of patients who require wound care only once a week. Discussion: The results of this study will be useful to improve the protocol for using platelet rich plasma in chronic vascular ulcers and to favour wider use of this treatment in primary care.

Uso pertinente del collarín cervical en el paciente traumático: una revisión sistemática.

Introducción y objetivo: El collarín cervical es un dispositivo que tiene como objetivo disminuir el movimiento del cuello para evitar lesiones secundarias en el manejo del paciente traumático en el ámbito prehospitalario. Mediante la realización de esta revisión sistemática se ha pretendido evaluar si la colocación del collarín cervical disminuye la movilidad del cuello en el paciente traumático, así como determinar si puede producir o evitar lesiones durante su manejo. Metodología: Revisión sistemática en base a las disposiciones PRISMA. Se elaboró un protocolo de búsqueda que se utilizó en cuatro bases de datos (Medline, Scopus, CINAHL y Web of Science) y se incluyeron ensayos clínicos y estudios observacionales publicados entre enero de 1995 y diciembre de 2014. Resultados: La revisión se realizó a partir de 10 ensayos clínicos no aleatorizados de modesta calidad metodológica: en 6 se utilizaron cadáveres con lesión cervical y en los otros 4 voluntarios sanos sin lesión cervical y un ensayo clínico aleatorizado de muestra pequeña realizado sobre cadáveres con lesión cervical. En los estudios realizados en pacientes sanos sin lesión cervical se observó que el collarín disminuía de forma significativa la movilidad del cuello frente a la no inmovilización. Por el contrario, en los estudios en los que participaban cadáveres con lesión cervical se determinó que el collarín cervical no disminuía la movilidad del cuello. Además en tres estudios se detectó un aumento de la separación intervertebral y en uno, un aumento de la presión venosa yugular. Conclusiones: Si bien la inmovilización cervical reduce la movilidad del cuello en pacientes sin lesión, este efecto no se produce en quienes presentan lesiones cervicales.